Complement and atherosclerosis-united to the point of no return?

Area of Science:

• Cardiovascular Research
• Immunology
• Atherosclerosis Pathogenesis

Background:

• Atherosclerosis is traditionally viewed as an inflammatory disease driven by oxidized LDL.
• The role of the complement system in atherogenesis requires re-evaluation.
• Existing concepts do not fully explain the initial stages of plaque formation.

Purpose of the Study:

• To propose a novel concept on atherogenesis focusing on LDL modification.
• To investigate the role of enzymatic LDL modification in initiating atherosclerosis.
• To differentiate the pathological process from physiological cholesterol clearance.

Main Methods:

• Review of existing literature on atherosclerosis and the complement system.
• Analysis of the immunological recognition of modified LDL.
• Histopathological examination of early foam cell formation.

Main Results:

• Enzymatic modification, not oxidation, of LDL is proposed as the trigger for innate immune recognition.
• Initial foam cell formation is suggested to be a non-inflammatory, reversible, physiological process.
• Atherosclerosis develops into a disease state when cholesterol clearance mechanisms are overwhelmed.

Conclusions:

• Enzymatically modified LDL (eLDL) is the key molecular trigger for atherosclerosis.
• The disease represents a unique immunopathological process driven by the innate immune system.
• Understanding this mechanism offers a new perspective on atherosclerosis treatment and prevention.